Walter Sunny Dzik

Walter Sunny Dzik

Auto-generated profile, based on publicly available information

Walter Sunny Dzik

Blood Transfusion Service and Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2006 in Transfusion
Verified
Journal Article
Closed access
PDF file
OAOmar I. Abdel‐Wahab
Omar I. Abdel‐Wahab
BHBrian Healy
Brian Healy
WDWalter H. Dzik
Walter H. Dzik

16 September 2002 in Transfusion
Verified
Journal Article
Closed access
PDF file
WDW.H. Dzik
W.H. Dzik
JAJ.K. Anderson
J.K. Anderson
EOE.M. O'Neill
E.M. O'Neill
SAS.F. Assmann
S.F. Assmann
LKL.A. Kalish
L.A. Kalish
CSC.P. Stowell
C.P. Stowell

1 January 2011 in Critical Care
Verified
Journal Article
Open access
PDF file
WDWalter H Dzik
Walter H Dzik
MBMorris A Blajchman
Morris A Blajchman
DFDean Fergusson
Dean Fergusson
MHMorad Hameed
Morad Hameed
BHBlair Henry
Blair Henry
BMBrian Muirhead
Brian Muirhead
In June 2011 the Canadian National Advisory Committee on Blood and Blood Products sponsored an international consensus conference on transfusion and trauma. A panel of 10 experts and two external advisors reviewed the current medical literature and information presented at the conference by invited international speakers and attendees. The Consensus Panel addressed six specific questions on the topic of blood transfusion in trauma. The questions focused on: ratio-based blood resuscitation in trauma patients; the impact of survivorship bias in current research conclusions; the value of nonplasma coagulation products; the role of protocols for delivery of urgent transfusion; the merits of traditional laboratory monitoring compared with measures of clot viscoelasticity; and opportunities for future research. Key findings include a lack of evidence to support the use of 1:1:1 blood component ratios as the standard of care, the importance of early use of tranexamic acid, the expected value of an organized response plan, and the recommendation for an integrated approach that includes antifibrinolytics, rapid release of red blood cells, and a foundation ratio of blood components adjusted by results from either traditional coagulation tests or clot viscoelasticity or both. The present report is intended to provide guidance to practitioners, hospitals, and policy-makers.

15 August 2003 in Transfusion
Verified
Journal Article
Closed access
PDF file
WDWalter H. Dzik
Walter H. Dzik

25 June 2003 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
WDW. H. Dzik
W. H. Dzik
MMM. F. Murphy
M. F. Murphy
GAG. Andreu
G. Andreu
NHN. Heddle
N. Heddle
CHC. Hogman
C. Hogman
TTthe Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society for Blood Transfusion
the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society for Blood Transfusion

8 November 2006 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
WDWalter H. Dzik
Walter H. Dzik
Summary: Hemovigilance programs from around the world document that the greatest risk to recipients of blood transfusion is human error, resulting in transfusion of the incorrect blood component. Errors in transfusion care have strong parallels with errors in medication administration. Errors often result from ‘lapse’ or ‘slip’ mistakes in which details of patient identification are overlooked. Three areas of transfusion are focal points for improved care: the labelling of the patient's pre‐transfusion sample, the decision to transfuse and the final bedside check designed to prevent mis‐transfusion. Both barcodes and radio‐frequency identification technology, each ideally suited to matching alpha‐numeric identifiers, are being implemented in order to improve performance sample labelling and the bedside check. The decision to transfuse should ultimately be enhanced through the use of nanotechnology sensors, computerised order entry and decision support systems. Obstacles to the deployment of new technology include resistance to change, confusion regarding the best technology, and uncertainty regarding the return‐on‐investment. By focusing on overall transfusion safety, deploying validated systems appropriate for both medication and blood administration, thoughtful integration of technology into bedside practice and demonstration of improved performance, the application of new technologies will improve care for patients in need of transfusion therapy.